AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02641808 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: no follicular flushing
Study NCT02159417 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic Education
Description: Realization of a consultation of educational diagnosis, followed by the participation for every patient to 4 educational collective workshops therapeutic:~* Knowledge of the disease~* Food~* Physical Activity and care of feet~* The therapeutics
Study NCT02836730 — intervention group
Intervention type: PROCEDURE
Intervention: Low back pain surgery
Study NCT00386178 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin E supplement rich in gamma tocopherol
Description: daily dose of Vitamin E supplement rich in gamma tocopherol
Study NCT03262909 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GelrinC
Description: Patients will undergo GelrinC implantation.
Study NCT03262909 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Microfracture historical control arm
Description: Patients undergo an arthroscopy for evaluation purposes, followed by lesion debridement, and a standard microfracture procedure.
Study NCT01583491 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: autologous platlet rich fibrin
Description: one dose immediate after surgery
Study NCT01583491 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: one side in control group
Description: control group insert any things after surgery
Study NCT03290872 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Carpentier Edwards Physio 2 Complete flexible mitral ring
Description: Mitral valve Annuloplasty Ring repair using a Carpentier Edwards Physio 2 Complete flexible mitral ring
Study NCT03290872 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Simplici T Partial flexible mitral annuloplasty ring
Description: Mitral valve Annuloplasty Ring repair using a Simplici T Partial flexible mitral annuloplasty ring
Study NCT01844518 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Abatacept
Study NCT01399515 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valproic Acid
Description: One 500mg tablet by mouth daily
Study NCT02157987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacuzimab spray
Study NCT02600572 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isometric exercises
Description: Subjects will perform one session of isometric exercises at the end of Day 1
Study NCT02600572 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eccentric exercises
Description: Subjects will perform one session of eccentric exercises at the end of Day 2
Study NCT01496612 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buspirone
Study NCT01496612 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01646723 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Volunteers Adding Life in Dementia (VALID) Program
Description: The VALID intervention will consist of 2 phases. First, volunteers will complete an assessment involving recording of a Life Story for each patient participant. This will include information on the patient's psychosocial history, occupational history, hobbies, interests and preferred activities using information from the LTC medical record and interviews with the patient and family members. Based on this information, a variety of potential psychosocial interventions will be developed for the individual with the assistance of the recreation therapist at the LTC. The second phase will involve implementation of the VALID intervention. Each individual with dementia will receive personalized pleasant activities for a minimum session of 30 minutes at a frequency of 3 times per week. One volunteer will complete the Life Story assessment and up to 3 volunteers may be involved with implementing the VALID program for each resident.
Study NCT01458938 — intervention group
Intervention type: OTHER
Intervention: treatment plan
Description: Data Collection Study
Study NCT04317469 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: VWF measurement
Description: Plasma levels of both vWF and IL.6 were be measured on T=0 i.e. (at start of the study once the patient considered to be risky for A.R.D.S development to obtain their baseline levels), T=48 (after 48 hours), and T=72 (after 72 hours).
Study NCT01678430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Study NCT01678430 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ofatumumab
Study NCT01678430 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorambucil
Study NCT01678430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Study NCT02818400 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: composite tissue allotransplantation
Study NCT01927172 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: AirSonea
Study NCT03995186 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioural activation
Description: 4-week programme based on the behavioural activation treatment provided in the NHS IAPT services. The programme includes psychoeducation on the relationship between activity and depression, examining the depressed person's level of activity, helping them identify activities they would like to increase and supporting them in the planning and conduct of those activities.
Study NCT03995186 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Activity monitoring
Description: 4-week programme where participants simply monitor their general daily activities in a diary.
Study NCT04600102 — intervention group
Intervention type: DEVICE
Intervention: Structure Sensor
Description: A 3D representation of each participant's lower limb geometry will be obtained using a Structure Sensor scanner (Occipital, Inc.) which uses an infrared structured light projector to construct a 3D image of an object. The scanner is connected to an iPad; to operate the user rotates the iPad camera around the desired object. In seconds, the entire geometry is digitally reconstructed.
Study NCT04505748 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Self-transfusion device
Description: The Transfusion filter set for salvaged blood (Summit Medical Ltd, Gloucestershire, UK) has been randomly used in 20 patients postoperatively. Patients, who received autologous blood, transfused with the collected amount of blood, only once, 6h postoperatively
Study NCT03002129 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: fluid challenge
Description: At two pre-defined time points during the procedure, enrolled patients will receive a fluid bolus of 5 ml/kg during 5 minutes
Study NCT02281292 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LKA651 ophthalmic solution
Study NCT01639300 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GNbAC1
Description: Single dose intravenous (IV) GNbAC1 2mg/kg or 6mg/kg
Study NCT01639300 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: GNbAC1 placebo
Description: Single dose intravenous (IV) GNbAC1 placebo
Study NCT00776373 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapamycin + high dose etoposide and cytarabine
Description: Rapamycin,by mouth, loading dose followed by a single daily dose for 8 days (dose level 1 = load of 9 mg followed by 3 mg daily doses, dose level 2 = 12 mg with daily doses of 4 mg; Etoposide 500 mg/m2/day IV and Cytarabine 2000 mg/m2/day IV every 24 hours for 4 days.
Study NCT00086385 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine polacrilex, Bupropion
Description: Subjects receive 12 weeks of bupropion treatment and 10 weeks of nicotine replacement.
Study NCT00086385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine polacrilex, Bupropion
Description: Subjects receive 12 weeks of bupropion treatment and 10 weeks of nicotine replacement.
Study NCT04613271 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Favipiravir
Description: Assignment of Administration Group 1:~Favipiravir 1600 mg twice a day at day 1 and 600 mg twice a day at day 7-14 + Azithromycin 500 mg once a day for 5 days.
Study NCT04613271 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Favipiravir
Description: Assignment of Administration Group 1:~Favipiravir 1600 mg twice a day at day 1 and 600 mg twice a day at day 7-14 + Azithromycin 500 mg once a day for 5 days.
Study NCT04613271 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: Azithromycin 500 mg once a day for 5 days.
Study NCT03624439 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard double-lumen tube
Description: intubation using standard double-lumen tube with Macintosh laryngoscope
Study NCT03624439 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Double-Lumen Tube Vivasight-DL
Description: intubation using Double-Lumen Video Tube Vivasight-DL with Macintosh laryngoscope
Study NCT00429572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30 mg/m\^2 intravenously Daily for 5 Days
Study NCT00429572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: 70 mg/m\^2 intravenously Daily for 2 Days
Study NCT00429572 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem Cell Infusion
Description: Stem Cell Infusion on Day 0.
Study NCT01953367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vantobra (tobramycin)
Description: Inhalation
Study NCT01953367 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TOBI (tobramycin)
Description: Inhalation
Study NCT02428933 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Bromocriptine
Description: The investigators will look at the physiological effect of dopamine on BAT activity rather than on the effect of the drug itself
Study NCT03372447 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxocobalamin 10,000mcg, Thiamin 100mg, Pyridoxine 50mg
Description: Single intramuscular dose of hydroxocobalamin 10,000mcg, Thiamin 100mg, Pyridoxine 50mg.
Study NCT05299645 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interview
Description: Pilot study with digital browsers
Study NCT01222897 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valacyclovir hydrochloride
Study NCT01222897 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valacyclovir hydrochloride
Study NCT03870906 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Occupational-specific health talk
Description: Health talk will provide information about hazards of tobacco (active smoking, second- and third-hand smoke), benefits of quitting smoking and methods to quit smoking.
Study NCT03870906 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Occupational-specific health talk
Description: Health talk will provide information about hazards of tobacco (active smoking, second- and third-hand smoke), benefits of quitting smoking and methods to quit smoking.
Study NCT03870906 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WhatsApp interaction
Description: Individual WhatsApp interactions last 3-month and consist of 2 parts. First part is regular WhatsApp message. The schedule will be adjusted according to the participants' quitting status. Second part is real-time discussion intervention based on participants' socio-demographic characteristics, smoking habit at baseline and updated smoking status obtained during online conversation. At 3-month follow-up, participants who are still smoking are encouraged to join an additional 1-month online group chat moderated by a smoking cessation counselor.
Study NCT03870906 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Phone follow-up/counselling service
Description: The intervention outcomes and participants' smoking status will be followed up regularly via telephone interviews (15 - 30 minutes).
Study NCT03870906 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phone follow-up/counselling service
Description: The intervention outcomes and participants' smoking status will be followed up regularly via telephone interviews (15 - 30 minutes).
Study NCT03870906 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Text message
Description: Participants will receive regular text messages with similar frequency to those in the intervention group.
Study NCT02606344 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mico-finance based intervention
Study NCT01712490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brentuximab vedotin
Description: Brentuximab vedotin (ADCETRIS®)1.2 mg/kg by IV infusion on Days 1 and 15 of each 28-day cycle.
Study NCT01712490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin
Description: Doxorubicin: 25 mg/m\^2 by IV infusion on Days 1 and 15 of each 28-day cycle.
Study NCT01712490 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicin
Description: Doxorubicin: 25 mg/m\^2 by IV infusion on Days 1 and 15 of each 28-day cycle.
Study NCT01712490 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bleomycin
Description: Bleomycin: 10 units/m\^2 by IV infusion on Days 1 and 15 of each 28-day cycle.
Study NCT02281292 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ranibizumab ophthalmic solution
Study NCT02281292 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Ranibizumab ophthalmic solution
Study NCT02223832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-128800
Study NCT01712490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinblastine
Description: Vinblastine: 6 mg/m2 will be administered by IV infusion on Days 1 and 15 of each 28-day cycle
Study NCT01712490 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vinblastine
Description: Vinblastine: 6 mg/m2 will be administered by IV infusion on Days 1 and 15 of each 28-day cycle
Study NCT01712490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dacarbazine
Description: Dacarbazine (DTIC): 375 mg/m\^2 by IV infusion on Days 1 and 15 of each 28-day cycle.
Study NCT01712490 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dacarbazine
Description: Dacarbazine (DTIC): 375 mg/m\^2 by IV infusion on Days 1 and 15 of each 28-day cycle.
Study NCT01820494 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Infant Formula
Description: Infant formula to be fed ad libitum
Study NCT03157336 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non Inferiority WTM Interventional Trial
Description: The intervention will implement the WTM cassava processing technique in participating households. Twenty women (in leading roles) will be our principal candidates to serve as peer trainers. Together with a 20 community health worker specialists, these women will be trained in the WTM technique by the Kinshasa team of community health workers who are experts in the WTM method. Those who master the technique will then be certified as trainers to train and support other small groups of other mothers throughout a two-year period in the implementation of the WTM for the safer processing of food for their families. Both the community health worker specialists and trained women (prospective trainers) would have to be able to bring the cassava cyanogenic content to the lowest achievable level, which must be \< 10 ppm as per the recommendations of the World Health Organization.
Study NCT01866813 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive training intervention group
Description: The intervention group will be asked to participate in an internet-delivered cognitive training pro-gram using the Danish edition of Scientific Brain Training Pro on their home personal computer. The software is provided through the Internet, and no software installation is needed onto the participant personal computer. Reminders to train will be provided by e-mail. The training involves working with the program for 40-60 minutes a day, five days a week, for six weeks.
Study NCT03619850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferumoxytol
Description: Each 20 mL single-use vial contains 17 mL of ferumoxytol that consists of iron at a concentration of 30 mg Fe/mL, coated with polyglucose sorbitol carboxymethylether and formulated with mannitol, at a concentration of 44 mg/mL, in a black to reddish brown sterile, aqueous, colloidal, isotonic solution.
Study NCT03619850 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iron sucrose
Description: Each mL contains 20 mg of elemental iron as iron sucrose in water for injection. The 5 mL single-use vial contains 100 mg of iron per 5 mL. The drug product contains approximately 30% sucrose (300 mg/mL).
Study NCT03085381 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HPV vaccine
Study NCT03085381 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01801189 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: One 300 mg oral dose of Pregabalin given before surgery.
Study NCT01801189 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for Pregabalin)
Description: One oral dose of placebo given before surgery.
Study NCT02021071 — intervention group
Intervention type: RADIATION
Intervention: XperGuide
Description: Live 3D image needle guidance which overlays live fluoroscopy and 3D soft tissue imaging data from previous acquired CT, MR or XperCT.
Study NCT02021071 — intervention group
Intervention type: RADIATION
Intervention: XperGuide with virtual path planning
Description: Instrument guidance allowing certain tasks that would normally occur using continuous X-ray guidance to be performed with reduced dose for patient and staff.
Study NCT00626834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vigabatrin
Description: Dose 1 BID
Study NCT00626834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vigabatrin
Description: Dose 2 BID
Study NCT00626834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vigabatrin
Description: Dose 3 BID
Study NCT00626834 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo
Description: Matching placebo BID
Study NCT04401410 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dose Finding Phase (MTD)
Description: Enrollment to the dose escalation phase will be staggered. The first patient enrolled on each of the 3 dose levels (DL1, DL2 and DL3) will have to complete the 14-day toxicity monitoring window prior to enrollment of the next patients. Prior to dose escalation, all patients at a particular dose level should have completed the minimum 14-day toxicity monitoring window before enrolling to a higher dose level.
Study NCT04401410 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Partially HLA-matched SARS-CoVSTs
Description: Infusion of SARS-CoVSTs at the MTD level as determined in the Dose Finding Phase
Study NCT04401410 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine care (no SARS-CoVSTs)
Description: Patients receive routine care for COVID19 per institutional standards (including antivirals such as remdesivir or other FDA-EUA approved products and thromboprophylaxis).
Study NCT04511338 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dialyzer with Endexo
Description: Sequence AB:~Period 1 Circuit A (Five Visits: 1,2,3,4,5) Period 2 Circuit B (Five Visits: 9,10,11,12,13)~Sequence BA:~Period 1 Circuit B (Five Visits: 1,2,3,4,5) Period 2 Circuit A (Five Visits: 9,10,11,12,13)
Study NCT01555736 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: grass (80%) and rye (20%) pollens allergoids
Description: comparison of two schemes of immunotherapy - preseasonal and perennial immunotherapy.
Study NCT00774956 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Exercise training program
Description: A 6 week shoulder exercise training program
Study NCT00774956 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Exercise training program
Description: A 6 week shoulder exercise training program
Study NCT02211950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 44847
Study NCT02211950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acarbose
Study NCT02211950 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Japanese diet
Study NCT02288442 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: Exercise training for 8 weeks (aerobic exercise, resistance training and inspiratory muscle training thrice a week)
Study NCT00651768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: budesonide/formoterol
Study NCT00651768 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Symbicort pMDI + budesonide HFA pMDI
Description: Symbicort 2 X 160/4.5mcg \& budesonide HFA pMDI 4 X 160mcg
Study NCT01706991 — intervention group
Intervention type: DEVICE
Intervention: Pediatric Vision Scanner eye scan
Description: Subject is scanned with a 2.5 second pediatric vision scanner device test.
Study NCT02281292 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Sham injection
Description: Mock injection administered as an empty hub without needle
Study NCT04067986 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Camrelizumab
Description: Camrelizumab One course will last 28 days.Intravenous injection at a dose of 200 mg, q2w~One course will last 28 days. Oral administration at a dose of 250 mg/d